Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Why Measuring Absolute Risk Of Fracture Could Save Many Broken Bones
A person"s absolute risk of fracture over the next 5 or 10 years can be predicted with reasonable accuracy according to their age, sex, bone density and history of fractures and falls.
pharmacy online
Washington, D.C., Church Addresses HIV Stigma, Teaches Safe Sex To Black, Gay Congregation
The Washington Post on Sunday featured Washington D.C.,-based Inner Light Ministries, a 16-year-old black community church with about 100 members, where many go "to share their experience of being black and gay, living and loving in a city where HIV and AIDS lurk in epidemic proportions. ò€¦" Some members of the congregation, as well as four of its leaders including Bishop Rainey Cheeks are HIV-positive. Cheeks teaches safe sex as a part of his sermons and the church provides condoms to its members. The article also discusses the stigma associated with HIV among gay black men. "Some men are reluctant to reveal their health status to possible partners for fear of being rejected," according to the Post. "That attitude, Cheeks said, is part of why gay black men in the District are disproportionately affected by HIV and AIDS. And why he has to keep preaching the message of safe sex," the article states (Fears, 7/26).
News of the day
Follow-Up Study Further Reinforces The Long-Term Benefits Of Tight Glucose Control In Early Treatment Of Diabetes
A study published in today"s issue of the Archives of Internal Medicine provides further reinforcement that tight control of blood glucose as soon as possible after a diagnosis of type 1 diabetes yields long-term benefits with regard to lowering the rates of eye, kidney and heart complications associated with diabetes. These findings stem from the landmark Diabetes Control and Complications Trial (DCCT) and its follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC), both funded by the National Institutes of Health.
Sexual Health

Vaxart Begins Animal Testing Of H1N1 Flu Vaccine Candidate

Vaxart, Inc., a biotechnology company focused on the development of oral vaccines, announced today that the company has created a candidate vaccine for H1N1 influenza (swine flu). On Saturday, May 23, Vaxart began testing for immune responses in animals, just 25 days after initiating the project. The company will compare performance of the research-grade H1N1 vaccine to its successful avian flu vaccine as a first step towards potential human clinical testing. The company has also begun preparing material suitable for production of human H1N1 vaccine; an initial batch could be produced by August. However, human testing may not begin until fall or later, due to the need for safety testing in animals. "Our oral vaccine could provide an important tool for swine flu pandemic preparation, because of the speed with which it could be delivered to groups such as first-line medical personnel," said Sean Tucker, Ph.D., Vaxart vice president of research. Currently, pandemic flu vaccines are prepared by a slow and inefficient process that requires about six months before the first large amounts of vaccine are available. This process depends on creating an engineered variant of the circulating pandemic influenza strain and growing it in eggs. An advantage of Vaxart"s approach is that it does not require culturing the flu virus in eggs; company scientists make a new vaccine by inserting a small piece of DNA matching the pandemic strain into Vaxart"s pre-constructed vector. Vaxart"s vector grows quickly and reproducibly in cell culture using a standard process. Vaxart vaccines are novel in several ways, including the fact that they can be taken orally (i.e., by swallowing a capsule). In addition, the product is stable enough to be distributed without refrigeration. In an emergency, an approved Vaxart vaccine could be supplied by mail, rather than risking the spread of disease caused by individuals visiting clinics to receive injections. Vaxart"s approach has important advantages over other platform technologies under development. Vaxart has shown that prior exposure to their platform vector does not impact the performance of later vaccinations. The company has previously demonstrated that its avian flu prototype vaccine has the ability to protect animals from lethal exposure to the pandemic strain. "We look forward to continuing our work with government authorities and funding agencies to pursue this very promising vaccine for H1N1 influenza," said Mark Backer, Ph.D., Vaxart CEO. About Vaxart Vaxart is a privately held biotechnology company focused on the development of oral vaccines. Vaxart"s proprietary approach is ideally suited for modular creation of vaccines, enabling the company to reduce development risk. Vaxart intends to apply its platform to develop a first-in-class vaccine for pandemic influenza, as well as creating oral alternatives to current vaccines such as annual influenza and HPV. The company expects to begin clinical testing of its pandemic flu vaccine in 2009. Vaxart, Inc


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009